This observational study aims to detect levels of iron, alpha-synuclein, and soluble lymphocyte activation gene 3 in acute ischemic stroke patients. And to see expressions of iron, alpha-synuclein, and lymphocyte activation gene 3 in the brain tissue of ischemic rats. The main questions it aims to answer are: * Is there an association between iron and alpha-synuclein accumulation in ischemic stroke? * Is there any change in soluble lymphocyte activation gene levels in ischemic stroke and if these levels are related to stroke severity and infarction size? . Can soluble lymphocyte activation gene levels be used as an early biomarker to diagnose ischemic stroke?
Age range
50 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Iron levels
Timeframe: 6 months
Alpha-synuclein levels
Timeframe: 6 months
Levels of Soluble lymphocyte activation gene-3
Timeframe: 6 months
levels of iron, alpha-synuclein, and soluble lymphocyte activation in relation to stroke severity and infarction size
Timeframe: 6 months
Iron levels in brain of rats
Timeframe: 2 months
Levels of Alpha-synuclein expression in brain of rats
Timeframe: 2 months
Levels of Lymphocyte activation gene-3 expression in brain of rats
Timeframe: 2 months